Novartis's Remibrutinib Succeeds in Phase III Multiple Sclerosis Trials
- Novartis reported positive topline Phase III results from the REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis, with the drug outperforming active comparator teriflunomide.
- Remibrutinib, an oral BTK inhibitor, reduced annualized relapse rate and inflammatory brain lesions versus teriflunomide across both identically designed studies.
- The trials also showed a positive trend toward slowing disability progression, with a meaningful signal in a preplanned combined analysis.
- Safety data were reassuring, showing no liver safety signal, consistent with remibrutinib's existing profile in chronic spontaneous urticaria.
- Novartis plans to present late-breaking data at an upcoming MS conference and pursue global regulatory submissions for this indication.
Beating teriflunomide isn't the same as beating the field's real benchmark — ocrelizumab, natalizumab, the high-efficacy therapies most MS neurologists already reach for first. Still, the safety data are the real story here. Hepatotoxicity has dogged this drug class, including flags on Sanofi's rival tolebrutinib program, so a clean liver readout is a genuine differentiator, not just noise. If remibrutinib's selectivity truly spares the liver, Novartis gets real separation in the BTK race rather than a me-too label. Add this to the existing CSU approval and Novartis is building an actual platform molecule — one asset, multiple indications, shared manufacturing and commercial muscle. The number to watch next: whether that disability-progression trend holds up, since that's what actually shifts prescribing.